9/20/2021- 9:15 a.m.
Washington – A Pfizer-BioNTech study has shown that their two-dose Covid-19 vaccine is “safe” and showed a “robust” antibody response in young children.
The trial was based on data from more than 2,000 kids aged 5-11, who received a low-dose jab – adding that the vaccine was “well tolerated” with side effects comparable to those seen in a study of people 16-25 who received their full dose.
Pfizer stated they will submit their data to the FDA for emergency use authorization by the end of September – with regulators expected to take up to a month to scrutinize the results and ascertain whether they believe the vaccine to be safe and effective for the age group.
